Dec 20, 2024 · Rhythm Pharmaceuticals is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.

Find the latest Rhythm Pharmaceuticals, Inc. (RYTM) stock quote, history, news and other vital information to help you with your stock trading and investing.

Rhythm is a biopharmaceutical company dedicated to transforming the lives of patients and their families living with hyperphagia (insatiable hunger) and severe obesity caused by rare MC4R pathway diseases. 1

Rhythm was founded in 2008 in Boston. Our lead asset, IMCIVREE® (setmelanotide), FDA-approved in 2020, is a precision medicine designed to treat severe obesity caused by an impairment of a pathway in the hypothalamus called the MC4R pathway.

BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE ...

At Rhythm, we know our work makes an important difference in the lives of patients and their families around the world. Every employee contributes to the company’s goal of discovering new treatments for rare diseases that no other company is developing.

Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and ...

Learn about Rhythm’s scientific research through key publications and recent conference presentations.

BOSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with...

Rhythm is guided by strong leadership at every level. We share an unrelenting drive to develop new therapies for rare neuroendocrine diseases, offering hope to patients and their families.